Health plans request reconsideration of US price-fixing claims over insulin
( September 29, 2025, 22:32 GMT | Official Statement) -- MLex Summary: Health plans asked a federal judge to reverse dismissal of their US price-fixing claims against pharmacy benefit managers over insulin, saying that the US District Court erred by determining they were indirect purchasers, rather than direct purchasers of the at-issue drugs from the PBMs. The health plans are the only true direct purchasers of the PBMs, meaning only they have paid alleged overcharges and only they can hold the PBMs accountable, the motion for reconsideration filed to the District of New Jersey said. "Because health plans are the only plaintiffs to directly pay the PBMs — and thus the only plaintiff with a claim against them — this Court's ruling would grant PBMs immunity from RICO and antitrust liability and effectively license them to inflate drug prices with impunity under federal RICO and antitrust laws," the filing said.See attached document: ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.